Serina Therapeutics, Inc.
SER · NYSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | -0.05 | 0.01 | -0.14 |
| FCF Yield | -6.09% | -7.81% | -10.36% | -5.01% |
| EV / EBITDA | -8.66 | -10.67 | -15.28 | 46.39 |
| Quality | ||||
| ROIC | -103.44% | -133.77% | -127.33% | -121.20% |
| Gross Margin | 87.69% | 0.00% | 500.00% | -300.00% |
| Cash Conversion Ratio | 0.84 | 0.58 | 0.90 | 1.67 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.08% | 40.37% | -100.00% | -47.22% |
| Free Cash Flow Growth | 13.23% | 5.92% | -54.94% | 62.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.91 | 0.84 | 1.27 | 5.69 |
| Interest Coverage | -618.33 | 0.00 | -326.41 | -332.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -9,596.25 | -6,289.41 | 0.00 | -2,634.11 |